Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

DNAY - Codex DNA Inc


Close
1.3
0.100   7.692%

Share volume: 19,956
Last Updated: Tue 03 Jan 2023 10:00:00 PM CET
Analytical Laboratory Instrument Manufacturing : -3.83%

PREVIOUS CLOSE
CHG
CHG%

$1.20
0.10
8.33%
This ticker is disabled and data are no longer maintained and up to date.
Fundamental analysis
0%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 0%
Performance
5 Days
9.24%
1 Month
-5.80%
3 Months
-19.25%
6 Months
-30.11%
1 Year
-86.60%
2 Year
-92.97%
Key data
Stock price
$1.30
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$1.08 - $11.02
52 WEEK CHANGE
-$0.86
MARKET CAP 
38.378 M
YIELD 
N/A
SHARES OUTSTANDING 
29.522 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
1.54
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$41,736
AVERAGE 30 VOLUME 
$63,305
Company detail
CEO:
Region: US
Website: codexdna.com
Employees: 0
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Analytical Laboratory Instrument Manufacturing
Sector: Manufacturing

Codex DNA is a synthetic biology company focused on enabling researchers to rapidly, accurately and reproducibly build or “write” high-quality synthetic DNA and mRNA that is ready to use in many downstream synthetic biology enabled markets. Codex DNA’s synthetic biology solution addresses the bottlenecks across the multi-step process of building DNA and mRNA, as well as the significant limitations of existing solutions that prevent the rapid building of virtually error-free DNA and mRNA at a useable scale. A key part of Codex DNA’s solution is the BioXp™ system, an end-to-end automated workstation that fits on the benchtop and is broadly accessible due to its ease-of-use and hands-free automation. Codex DNA believes the BioXp™ system can democratize synthetic biology by simplifying the process of building DNA and mRNA, thereby accelerating the discovery, development, and production of novel high-value products, including antibody-based biologics, mRNA-based vaccines and therapeutics and precision medicines.

Recent news